作者
Nasser Hanna, David Johnson, Sarah Temin, Sherman Baker Jr, Julie Brahmer, Peter M Ellis, Giuseppe Giaccone, Paul J Hesketh, Ishmael Jaiyesimi, Natasha B Leighl, Gregory J Riely, Joan H Schiller, Bryan J Schneider, Thomas J Smith, Joan Tashbar, William A Biermann, Gregory Masters
发表日期
2017/10/20
期刊
Journal of Clinical Oncology
卷号
35
期号
30
页码范围
3484-3515
出版商
American Society of Clinical Oncology
简介
Purpose
Provide evidence-based recommendations updating the 2015 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC).
Methods
The ASCO NSCLC Expert Panel made recommendations based on a systematic review of randomized controlled trials from February 2014 to December 2016 plus the Cancer Care Ontario Program in Evidence-Based Care’s update of a previous ASCO search.
Results
This guideline update reflects changes in evidence since the previous guideline update. Fourteen randomized controlled trials provide the evidence base; earlier phase trials also informed recommendation development.
Recommendations
New or revised recommendations include the following. Regarding first-line treatment for patients with non–squamous cell carcinoma or squamous cell carcinoma (without positive markers, eg, EGFR/ALK/ROS1), if the patient has high …
学术搜索中的文章
N Hanna, D Johnson, S Temin, S Baker Jr, J Brahmer… - Journal of Clinical Oncology, 2017
